Corifact Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to recognition of fibrinogen deficiency, trauma care advancements, surgical bleeding management protocols, plasma derived therapy approvals, hospital adoption.

The growth in the forecast period can be attributed to growth in emergency surgeries, aging population needs, trauma center expansion, improved coagulation diagnostics, demand for rapid hemostatic agents. Major trends in the forecast period include increased use of fibrinogen concentrates, focus on rapid bleeding control, expansion of trauma and surgical care, hospital based hemostasis management, rising adoption in liver disease treatment.

The rising prevalence of bleeding disorders is expected to drive the growth of the Corifact market in the coming years. Bleeding disorders are conditions that hinder the blood’s ability to clot properly, resulting in excessive or prolonged bleeding. This increase can be attributed to improved diagnostic methods, greater awareness, advances in genetic testing, as well as lifestyle changes and the prevalence of underlying health conditions. Corifact is used to treat bleeding disorders caused by factor XIII deficiency by replacing the missing clotting factor, aiding in the formation of stable blood clots and reducing excessive bleeding. For example, in December 2023, a report from the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) highlighted the burden of bleeding disorders in 2023/24, documenting 6,835 individuals with haemophilia A, 1,378 with haemophilia B, 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the growing prevalence of bleeding disorders is fueling the expansion of the Corifact market.

The increasing number of surgical procedures is expected to support the growth of the Corifact market. Surgical procedures are medical interventions performed to treat injuries, diseases, or abnormalities using manual or instrumental methods. The rise in surgical procedures is largely driven by an aging population needing treatment for age-related conditions, as well as advancements in minimally invasive technologies, which make surgeries safer and more accessible. Corifact is used during surgeries to prevent and control excessive bleeding in patients with congenital factor XIII deficiency by stabilizing blood clots and promoting wound healing. For instance, in June 2024, the American Society of Plastic Surgeons, a US-based specialty organization, reported a 7% increase in minimally invasive procedures in 2023, surpassing surgical procedures by 2%, with neuromodulator injections and hyaluronic acid fillers reaching over 9 million and 5 million treatments, respectively. Therefore, the growing number of surgical procedures is driving the Corifact market.

The rising demand for biological products is expected to further propel the growth of the Corifract market. Biological products are complex pharmaceuticals derived from living organisms, used to diagnose, prevent, treat, or cure medical conditions. This increasing demand is driven by environmental concerns, heightened consumer awareness, and the need for sustainable and effective alternatives to synthetic chemicals. Corifract enhances biological products by improving their stability, bioavailability, and efficacy, ensuring optimal performance and longer shelf life through advanced formulation and delivery solutions. For example, in August 2025, the Assistant Secretary for Planning and Evaluation, a US-based government department, reported that net revenue for biosimilars can range from a USD 33.5 million loss in smaller markets to USD 9.5 billion in larger markets. Proposed regulatory changes, including universal interchangeability, the use of a global comparator, and removal of comparative efficacy studies, are estimated to reduce development costs and increase lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Therefore, the rising demand for biological products is driving the growth of the Corifract market.

Major companies operating in the corifact market are CSL Behring.

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the corifact market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the corifact market by increasing costs associated with plasma fractionation, sterile manufacturing supplies, and cold chain distribution. These effects are most evident in hospital pharmacies and trauma centers across europe and asia pacific. Import duties have contributed to higher procurement costs for fibrinogen concentrates. Distribution timelines have also been affected by regulatory trade controls. At the same time, tariffs are supporting domestic plasma processing and enhancing supply reliability.

The corifact market research report is one of a series of new reports that provides corifact market statistics, including corifact industry global market size, regional shares, competitors with a corifact market share, detailed corifact market segments, market trends and opportunities, and any further data you may need to thrive in the corifact industry. This corifact market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Corifact is a fibrinogen concentrate used in medical treatments to control bleeding, especially in patients with fibrinogen deficiency or low fibrinogen levels, which may result from trauma, surgery, or liver disease. It aids blood clotting by supplying fibrinogen, a protein crucial for clot formation.

The main products in Corifact include human-derived factor XIII and recombinant factor XIII. Human-derived factor XIII (FXIII) is a protein that plays a role in the final stages of blood clotting. Its therapeutic uses include routine prophylactic treatment and perioperative management. Distribution occurs through hospital pharmacies, specialty pharmacies, and outpatient clinics.

The corifact market consists of sales of products including fibrinogen concentrates, factor concentrates, coagulation factor products, cryoprecipitate, and recombinant clotting factors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.